L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors - Takeaways - MDSpire

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors

  • By

  • Alessandro Zampogna

  • Luigi Borzì

  • Domiziana Rinaldi

  • Gabriele Imbalzano

  • Martina Patera

  • Marco Falletti

  • Carlo Alberto Artusi

  • Edoardo Bianchini

  • Leonardo Lopiano

  • Gabriella Olmo

  • Antonio Suppa

  • June 15, 2026

  • 0 min

Share

  • 1

    This study evaluated the impact of L-Dopa/Carbidopa intestinal gel (LCIG) on motor performance in advanced Parkinson’s disease patients using wearable sensors.

  • 2

    Patients receiving LCIG exhibited less severe motor fluctuations and lower intra-day variability in gait parameters compared to those on oral dopaminergic therapy.

  • 3

    Dyskinesia duration was similar between patients treated with LCIG and those on oral therapy, indicating comparable levels of involuntary movements.

  • 4

    Wearable sensor technology effectively captured real-world motor performance variability, highlighting its potential for clinical management of Parkinson’s disease.

  • 5

    The findings suggest that continuous dopaminergic delivery via LCIG may provide more stable motor control throughout the day in advanced Parkinson’s disease patients.

Original Source(s)

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors

  • by Alessandro Zampogna, Luigi Borzì, Domiziana Rinaldi, Gabriele Imbalzano, Martina Patera, Marco Falletti, Carlo Alberto Artusi, Edoardo Bianchini, Leonardo Lopiano, Gabriella Olmo, Antonio Suppa

  • June 15, 2026

Related Content

Advancing rehabilitation in Parkinson’s disease through virtual reality: a narrative review

Exploration of the longitudinal clinical course and potential prognostic factors in Parkinson’s disease: 2.5-year observational study in Japan

Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias